Updated Jul 16, 2026
Fabbio Patrick is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days.

Patrick Fabbio is the Chief Financial Officer of Protara Therapeutics, Inc. (ticker: TARA) according to the most recent SEC filing dated 2026-01-21. The filing indicates no reported equity purchases or sales by the CFO during that period. Based on the SEC context, he leads the company's financial planning, accounting, and investor relations in support of Protara's focus on therapies for cancer and rare diseases.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-27 | TARA | Protara Therapeutics, Inc. | F — Tax withholding / forfeiture | 3.3K | $6.67 | $22K |
| 2026-01-22 | TARA | Protara Therapeutics, Inc. | F — Tax withholding / forfeiture | 3.1K | $5.60 | $17K |
| 2026-01-21 | TARA | Protara Therapeutics, Inc. | A — Grant or award | 28.0K | $0.00 |
Patrick Fabbio is the Chief Financial Officer of Protara Therapeutics, Inc. (ticker: TARA) according to the most recent SEC filing dated 2026-01-21. The filing indicates no reported equity purchases or sales by the CFO during that period. Based on the SEC context, he leads the company's financial planning, accounting, and investor relations in support of Protara's focus on ther…
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Fabbio Patrick profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.